[go: up one dir, main page]

BRPI0511703A - composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição - Google Patents

composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição

Info

Publication number
BRPI0511703A
BRPI0511703A BRPI0511703-8A BRPI0511703A BRPI0511703A BR PI0511703 A BRPI0511703 A BR PI0511703A BR PI0511703 A BRPI0511703 A BR PI0511703A BR PI0511703 A BRPI0511703 A BR PI0511703A
Authority
BR
Brazil
Prior art keywords
diabetes
type
diabetes mellitus
treating
syndrome
Prior art date
Application number
BRPI0511703-8A
Other languages
English (en)
Inventor
Emma R Parmee
Yusheng Xiong
Jian Guo
Rui Liang
Linda Brockunier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0511703A publication Critical patent/BRPI0511703A/pt
Publication of BRPI0511703B1 publication Critical patent/BRPI0511703B1/pt
Publication of BRPI0511703B8 publication Critical patent/BRPI0511703B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS DE TRATAR DIABETE MELITO TIPO 2, DE RETARDAR O INìCIO DO DIABETE MELITO TIPO 2, DE TRATAR HIPERGLICEMIA, DIABETE OU RESISTêNCIA à INSULINA, OBESIDADE, SìNDROME X, UM DISTúRBIO LIPìDICO, ATEROSCLEROSE, E UMA CONDIçãO São descritos pirazóis tendo um grupo naftila ligado. Os compostos são úteis para tratar a diabetes tipo 2 e condições relacionadas. São também incluídos composições farmacêuticas e métodos de tratamento.
BRPI0511703A 2004-06-04 2005-05-31 composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição BRPI0511703B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04
PCT/US2005/018828 WO2005121097A2 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use

Publications (3)

Publication Number Publication Date
BRPI0511703A true BRPI0511703A (pt) 2008-01-08
BRPI0511703B1 BRPI0511703B1 (pt) 2018-07-17
BRPI0511703B8 BRPI0511703B8 (pt) 2021-05-25

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511703A BRPI0511703B8 (pt) 2004-06-04 2005-05-31 composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição

Country Status (34)

Country Link
US (2) US7598285B2 (pt)
EP (1) EP1756064B1 (pt)
JP (2) JP4108739B2 (pt)
CN (1) CN1964947A (pt)
AR (2) AR049291A1 (pt)
AT (1) ATE395338T1 (pt)
AU (2) AU2005252183B2 (pt)
BR (1) BRPI0511703B8 (pt)
CA (1) CA2566945C (pt)
CR (1) CR8766A (pt)
CY (1) CY1108544T1 (pt)
DE (1) DE602005006806D1 (pt)
DK (1) DK1756064T3 (pt)
EA (1) EA012431B1 (pt)
EC (1) ECSP067062A (pt)
ES (1) ES2306165T3 (pt)
GE (1) GEP20094605B (pt)
HR (1) HRP20080311T3 (pt)
IL (1) IL179754A (pt)
MA (1) MA28673B1 (pt)
MX (1) MXPA06014084A (pt)
MY (1) MY143599A (pt)
NI (1) NI200600290A (pt)
NO (1) NO339149B1 (pt)
NZ (1) NZ551405A (pt)
PE (1) PE20060427A1 (pt)
PL (1) PL1756064T3 (pt)
PT (1) PT1756064E (pt)
SI (1) SI1756064T1 (pt)
TN (1) TNSN06397A1 (pt)
TW (1) TWI293952B (pt)
UA (1) UA85884C2 (pt)
WO (1) WO2005121097A2 (pt)
ZA (1) ZA200609489B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
JP2008507528A (ja) * 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
EP1910303A2 (en) 2005-07-26 2008-04-16 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2008087029A1 (en) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2170337A4 (en) * 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
CA2717138A1 (en) 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
WO2009140342A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010039789A1 (en) * 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
JP5694561B2 (ja) 2010-12-23 2015-04-01 ファイザー・インク グルカゴン受容体モジュレーター
KR101638671B1 (ko) 2011-02-08 2016-07-11 화이자 인코포레이티드 글루카곤 수용체 조절자
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN118236497A (zh) 2016-08-30 2024-06-25 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
EP3752249A1 (en) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0948257A4 (en) 1996-11-20 1999-12-29 Merck & Co Inc TRIARYL-SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME AND METHOD FOR THEIR USE
AU726311B2 (en) 1996-11-20 2000-11-02 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
AU730295B2 (en) 1996-11-20 2001-03-01 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
WO1998025907A1 (en) * 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
NZ500141A (en) 1997-04-18 2002-05-31 G Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DK1042293T3 (da) 1997-12-19 2008-07-14 Amgen Inc Substituerede pyridin- og pyridazinforbindelser og deres farmaceutiske anvendelse
DE69939481D1 (de) 1998-09-17 2008-10-16 Bristol Myers Squibb Co Methode zur behandlung von diabetes die einen ap2-inhibitor und dazugehörige kombinationen verwendet
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
AU5841400A (en) * 1999-08-10 2001-03-05 Nihon Bayer Agrochem K.K. Herbicidal tetrazolinone derivatives
IL149493A0 (en) * 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2002008188A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
CA2473591C (en) * 2002-02-01 2011-11-01 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
MXPA05000816A (es) 2002-07-19 2005-04-28 Baxter Int Sistemas y metodos para realizar dialisis peritoneal.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
AU2003298889A1 (en) * 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
WO2004069158A2 (en) * 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2522080A1 (en) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
WO2004100875A2 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
JP2008507528A (ja) * 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
PE20060427A1 (es) 2006-06-19
EP1756064B1 (en) 2008-05-14
UA85884C2 (uk) 2009-03-10
IL179754A0 (en) 2007-05-15
NZ551405A (en) 2009-06-26
CN1964947A (zh) 2007-05-16
MA28673B1 (fr) 2007-06-01
AU2008229701C1 (en) 2010-07-29
DE602005006806D1 (de) 2008-06-26
HRP20080311T3 (hr) 2008-07-31
TNSN06397A1 (en) 2008-02-22
ZA200609489B (en) 2007-10-31
CA2566945C (en) 2010-09-21
TWI293952B (en) 2008-03-01
US20090176854A1 (en) 2009-07-09
TW200604179A (en) 2006-02-01
PL1756064T3 (pl) 2008-11-28
BRPI0511703B8 (pt) 2021-05-25
EP1756064A2 (en) 2007-02-28
EA200602196A1 (ru) 2007-06-29
GEP20094605B (en) 2009-02-10
PT1756064E (pt) 2008-07-22
JP2008505062A (ja) 2008-02-21
AU2005252183B2 (en) 2008-07-17
AU2005252183A1 (en) 2005-12-22
SI1756064T1 (sl) 2008-12-31
EA012431B1 (ru) 2009-10-30
JP4733153B2 (ja) 2011-07-27
ATE395338T1 (de) 2008-05-15
WO2005121097A3 (en) 2006-02-16
IL179754A (en) 2013-12-31
NI200600290A (es) 2007-08-07
US7799818B2 (en) 2010-09-21
AR049291A1 (es) 2006-07-12
ECSP067062A (es) 2007-01-26
JP4108739B2 (ja) 2008-06-25
ES2306165T3 (es) 2008-11-01
NO339149B1 (no) 2016-11-14
JP2008150388A (ja) 2008-07-03
WO2005121097A2 (en) 2005-12-22
AR088919A2 (es) 2014-07-16
NO20070073L (no) 2007-03-05
AU2008229701B2 (en) 2010-03-04
MY143599A (en) 2011-06-15
DK1756064T3 (da) 2008-09-22
AU2008229701A1 (en) 2008-10-30
US20050272794A1 (en) 2005-12-08
US7598285B2 (en) 2009-10-06
BRPI0511703B1 (pt) 2018-07-17
CA2566945A1 (en) 2005-12-22
MXPA06014084A (es) 2007-02-15
CR8766A (es) 2007-08-28
CY1108544T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
EA201000321A1 (ru) Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BR0210383A (pt) compostos para o tratamento de distúrbios metabólicos
CL2007002187A1 (es) Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
BR112021016782A2 (pt) Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BRPI0814825A2 (pt) Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION. (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DHOME CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2725 DE 28-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.